Get the Stockscreener App
235.76
0.03%
0.07
After Hours:
235.76
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $235.76, with a volume of 1.59M.
It is up +0.03% in the last 24 hours and up +16.09% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
See More
Previous Close:
$235.69
Open:
$233.06
24h Volume:
1.59M
Relative Volume:
1.05
Market Cap:
$34.01B
Revenue:
$5.54B
Net Income/Loss:
$1.52B
P/E Ratio:
22.73
EPS:
10.3734
Net Cash Flow:
$1.74B
1W Performance:
+3.20%
1M Performance:
+16.09%
6M Performance:
-8.00%
1Y Performance:
-16.39%
1-Day Range:
$232.29
$237.94
1-Week Range:
$228.54
$238.37
52-Week Range:
$180.26
$284.87
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
235.76 | 32.95B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
367.07 | 132.30B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
188.13 | 51.11B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
72.23 | 35.25B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
34.65 | 28.58B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | JP Morgan | Overweight |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
XY Capital Ltd Buys Shares of 36,769 ResMed Inc. $RMD - MarketBeat
Paralel Advisors LLC Buys Shares of 10,293 ResMed Inc. $RMD - MarketBeat
SGL Investment Advisors Inc. Purchases New Position in ResMed Inc. $RMD - MarketBeat
Wealthfront Advisers LLC Makes New Investment in ResMed Inc. $RMD - MarketBeat
13,498 Shares in ResMed Inc. $RMD Purchased by Fairtree Asset Management Pty Ltd - MarketBeat
Danske Bank A S Makes New Investment in ResMed Inc. $RMD - MarketBeat
Bank of New York Mellon Corp Takes $818.03 Million Position in ResMed Inc. $RMD - MarketBeat
Baird Mid Cap Growth Fund's ResMed Inc(RMD) Holding History - GuruFocus
ResMed Stock Bounces Back 4% This Week After Erasing Its Post Earnings Selloff - TIKR.com
ResMed (RMD) Today: Moves 0.67% Down to $228.44 in the Latest Session; Range Check: Price Remains Between $217.02 Support and $239.86 Resistance in the Current UpdateInvestment Factor - Vinanet
ResMed (RMD) Levels: Slides 0.10% to $229.76 on the Day; Current Setup: Traders Can Monitor the $218.27-$241.25 Range on the DayIV Spike - Vinanet
ResMed (NYSE:RMD) Faces Fresh Market Attention - Kalkine Media
ResMed stock climbs after earnings beat as analysts see valuation full - Ad-hoc-news.de
ResMed (NYSE:RMD) Upgraded to Hold at Rothschild & Co Redburn - MarketBeat
Rothschild & Co Redburn Initiates ResMed(RMD.US) With Hold Rating, Announces Target Price $230 - Moomoo
350,860 Shares in ResMed Inc. $RMD Acquired by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
BlackRock Inc. Makes New $2.40 Billion Investment in ResMed Inc. $RMD - MarketBeat
ResMed (RMD): Finishes 4.85% Up at $230.65 in the Current Update; Price Levels: Traders Can Monitor the $219.12-$242.18 Range at the CloseBreadth Thrust - Vinanet
Is It Too Late to Buy ResMed Inc (RMD) After 4.8% Rally? GF Value Says Undervalued - GuruFocus
ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
Resmed Inc Stock (RMD) Moved Up by 3.43% on Aug 19: What Investors Need To Know - TradingKey
ResMed, Inc.: Target Price Consensus and Analysts Recommendations | RME | US7611521078 - marketscreener.com
Oxbow Advisors LLC Invests $5.57 Million in ResMed Inc. $RMD - MarketBeat
Rothschild Redburn initiates ResMed stock coverage with neutral rating By Investing.com - Investing.com South Africa
Rothschild Redburn initiates ResMed stock coverage with neutral rating - Investing.com
Deutsche Bank AG Takes Position in ResMed Inc. $RMD - MarketBeat
Resmed Announces Board Leadership Transition and Director Retirement - The Globe and Mail
ResMed stock slips as Q4 revenue rose 9% - AD HOC NEWS
Resmed board set to get new lead director - HME News
RESMED INC CDI COM USD0.004 (10CDI/1SHS) To Go Ex-Dividend On August 19th, 2026 With 0.066 USD Dividend Per Share - Moomoo
UNIVEST FINANCIAL Corp Acquires Shares of 12,846 ResMed Inc. $RMD - MarketBeat
Perigon Wealth Management LLC Invests $4.60 Million in ResMed Inc. $RMD - MarketBeat
5,358 Shares in ResMed Inc. $RMD Purchased by Flputnam Investment Management Co. - MarketBeat
Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor - Koreabizwire
ResMed (ASX:RMD) Faces Market Attention as Healthcare Technology Portfolio Continues to Evolve - Kalkine
ResMed (RMD) Announces Auditor Transition to PwC and Board Leade - GuruFocus
ResMed Replaces KPMG with PwC and Names Carol Burt as Lead Director - Kalkine
ResMed names Carol Burt as lead director, Ron Taylor to retire - Investing.com
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
Resmed Names Carol Burt Lead Director as Ron Taylor Retires After 21 Years on Board - Quiver Quantitative
A lead director's 21-year Resmed tenure is set to end in November - Stock Titan
ResMed’s (RMD) Sleep Business Booms Even As One Product Stumbles - Yahoo Finance
ResMed Inc. (RMD) Stock Analysis: Assessing a 10% Potential Upside in Healthcare Innovation - DirectorsTalk Interviews
ResMed names Carol Burt lead director as Ron Taylor steps down - Bitget
Could Cochlear (ASX:COH) and ResMed (ASX:RMD) Shape the Next Chapter? - Kalkine Media
87,722 Shares in ResMed Inc. $RMD Purchased by Avalon Trust Co - MarketBeat
41,381 Shares in ResMed Inc. $RMD Acquired by ABN AMRO Bank N.V. - MarketBeat
Why You Should Consider Buying ResMed Stock After Its First-Ever Annual Guide - TIKR.com
The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call - Yahoo Finance
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
ResMed Inc.: Financial Data Forecasts Estimates and Expectations | RMEA | AU000000RMD6 - marketscreener.com
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.61%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):